MiGenTra develops biosimilars, cell and gene therapies, and vaccines to enhance access to high-quality medicines in Egypt, the Middle East, and Africa. By leveraging local manufacturing capabilities and expertise from ProBioGen and Minapharm Pharmaceuticals, the company addresses the need for affordable healthcare solutions in the region.
Funding
Funding not disclosed
Founders
Product
Problem
Healthcare systems in Africa and the Middle East face significant challenges, including a disproportionate share of the global disease burden, limited access to healthcare services in rural areas, and the high cost of biologic treatments. This results in delayed diagnoses and poor outcomes for patients in the region.
Solution
MiGenTra develops and commercializes high-quality, affordable biologic medicines, including biosimilars, cell and gene therapies, and vaccines, to address unmet medical needs in Africa and the Middle East. By leveraging the scientific and manufacturing expertise of its parent companies, ProBioGen and Minapharm Pharmaceuticals, MiGenTra aims to strengthen regional and local manufacturing capacity and expand access to key healthcare transforming medicines. The company's holistic approach focuses on therapies, reach, and transformation to improve healthcare outcomes in the region.
Target Audience
MiGenTra's primary target audience includes patients, healthcare providers, and healthcare systems in Africa and the Middle East seeking access to affordable, high-quality biologic medicines.
Features
- Development of biosimilars, cell and gene therapies (CGT), and vaccines
- Focus on high-quality medicines at affordable prices
- Leveraging scientific and manufacturing expertise from ProBioGen and Minapharm Pharmaceuticals
- Aim to strengthen regional and local manufacturing capacity in Africa and the Middle East
- Adalimumab biosimilar candidate (Adessia®) in Phase 1 clinical trials